CRISPR Therapeutics - Business Information
Manufacturing · Switzerland · 473 Employees
Crispr Therapeutics, founded in 2013 and headquartered in Zug, Switzerland, is a developer of gene-based medications that target diseases at the molecular level.Read More
View Company Info for Free
Who is CRISPR Therapeutics
Headquarters
14 Baarerstrasse, Zug, Zug, 6300, Switzerland
Phone Number
+41 415613277
Website
Revenue
$915.4M
Stock Symbol
CRSP
Industry
CRISPR Therapeutics Org Chart
CRISPR Therapeutics Company Metrics
Funding
Funding DateOct 18, 2016
RoundStock Issuance/Offering
Amount$56M
Investors
See More
$56M
Total Funding Amount
$56M
Most Recent Funding Amount
1
Number of Funding Rounds
CRISPR Therapeutics News & Media
CRISPR Therapeutics AG (NASDAQ:CRSP) is a favorite amongst institutional investors who own 66%
Key Insights Institutions' substantial holdings in CRISPR Therapeutics implies that they have significant influence...CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
ZUG, Switzerland and CAMBRIDGE, Mass., June 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at the 44th Annual Goldman Sachs Global Healthcare Conference being held from June 12th- 15th, 2023.Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that both pivotal trials for exagamglogene autotemcel (exa-cel) in patients with transfusion-dependent beta thalassemia (TDT) or severe sickle cell disease (SCD) met primary and key secondary endpoints at pre-specified interim analyses. The results are being presented at the Annual European Hematology Association (EHA) Congress. “The updated resul
Read more news
Frequently Asked Questions regarding CRISPR Therapeutics
Crispr Therapeutics, founded in 2013 and headquartered in Zug, Switzerland, is a developer of gene-based medications that target diseases at the molecular level.... Read More